| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
Xanthine oxidase-IN-18 (MT7) showed no cytotoxicity to L929 mouse fibroblasts at concentrations up to 100 μM[1]. Xanthine oxidase-IN-18 exhibited approximately twice the inhibitory effect on MDA-MB-231 breast cancer cells (IC50 = 1.24 μM) compared to its inhibitory effect on A549 lung cancer cells (IC50 = 3.04 μM), confirming its inhibitory effect on intracellular xanthine oxidase (XO)[1]. Xanthine oxidase-IN-18 (1-10 μM, 24 h) showed significant concentration-dependent reactive oxygen species (ROS) scavenging activity in RAW 264.7 macrophages[1]. Xanthine oxidase-IN-18 (48 hours) inhibited superoxide dismutase (SOD) by 66%, glutathione reductase (GR) by 49%, and hydrogen peroxide detoxification enzyme by 38% [1].
|
|---|---|
| ln Vivo |
Xanthine oxidase-IN-18 (10, 20, and 40 mg/kg, by gavage, single dose, 1 hour after potassium oxonate injection) reduced blood uric acid in a Potassium oxonate-induced hyperuricemia-suggestive model [1]. Xanthine oxidase-IN-18 (5, 50, and 300 mg/kg, by gavage, single dose) did not cause death and no toxicity was observed in a sudden interruption toxicity study in SD [1].
|
| Cell Assay |
Cell Viability Assay[1]
Cell Types: RAW 264.7 macrophages Tested Concentrations: 1, 5 and 10 μM Incubation Duration: 24 h Experimental Results: Showed no significant reduction in cell viability at any tested concentration. |
| Animal Protocol |
Animal/Disease Models: SD Rats (202 ± 20 g) intraperitoneally injected with Potassium oxonate (300 mg/kg)[1]
Doses: 10, 20 and 40 mg/kg Route of Administration: i.g., single dose 1 h after Potassium oxonate Experimental Results: Showed a significant reduction in serum uric acid compared with the model group after 2 h. Exhibited a dose-dependent decrease in uric acid levels. Showed comparable anti-hyperuricemia effects at 40 mg/kg to Febuxostat. Did not cause any significant changes in creatinine or urea nitrogen levels in rats. Did not produce any harmful effects on the liver or kidneys. Animal/Disease Models: SD Rats (202 ± 20 g)[1] Doses: 5, 50 and 300 mg/kg Route of Administration: p.o, single dose Experimental Results: None of rats died during the experiment, indicating that it was safe at the dose level of 300 mg/kg. Exhibited no signs of toxicity in major organs after 14 days in the 300 mg/kg group. |
| References |
| Molecular Formula |
C23H25N3O5
|
|---|---|
| Molecular Weight |
423.46
|
| Appearance |
Typically exists as solids at room temperature
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3615 mL | 11.8075 mL | 23.6150 mL | |
| 5 mM | 0.4723 mL | 2.3615 mL | 4.7230 mL | |
| 10 mM | 0.2361 mL | 1.1807 mL | 2.3615 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
